Saturday 7 November 2026 Export OTLK’s income statement to Excel — free account

Outlook Therapeutics, Inc.

OTLK Healthcare Biotechnology

Outlook Therapeutics, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $1.4 million.

Revenue: −99.4%
EPS: +72.7%
Free cash flow: −76.5%
Total debt: −47.1%

Quarter to June 2026, against a year earlier

Insider buying

0.43 0.01 −2.27%

Follow OTLK

Alert me

Market cap: $106.9M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: n/a
Altman Z: −58.86
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 7.87

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	5	1	1	3	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 106.90

Revenue ttm (1.16)

Net income ttm (61.12)

Free cash flow ttm (56.15)

Net debt Q 6.98

Valuation

P/E 0.00

Forward P/E (0.81)

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.81

Debt / equity Q (1.75)

Interest coverage Q (80.42)

Growth

Revenue growth Q −99.42%

Operating income growth Q +31.36%

EPS, this year +73.00%

EPS, next year A +53.10%

Revenue, next year A −51.70%

EPS, past 5 yrs —

EPS, next 5 yrs A +56.24%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	23	15	8	11
Receivables	—	—	1	2
Inventory	—	—	3	5
Other	—	—	—	—
	31	27	17	23

	2023	2024	2025	Q'26
Payables	7	8	10	7
ST’ Debt	36	29	30	18
Other	—	—	—	—
	47	43	46	29

Compound Annual Growth %

	10y	5y	3y
Sales	—	(22.99%)	(28.15%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.09 Actual −0.09

−0.25 −0.20 −0.15 −0.11 −0.06

Q4 FY25 Beat +0.01

Q1 FY26 Miss −0.05

Q2 FY26 Miss −0.04

Q3 FY26 Met 0.00

Q4 FY26 — Dec 18

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.23	−0.22	Beat by 0.01
Q1 FY26	−0.17	−0.22	Miss by 0.05
Q2 FY26	−0.12	−0.16	Miss by 0.04
Q3 FY26	−0.09	−0.09	Met by 0.00
Q4 FY26	−0.08	—	Reports 18 December 2026

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.38)	(0.05)	(0.15)	—	—
’25	0.72	(1.50)	(0.55)	(0.28)	(1.79)
’24	(0.80)	(8.01)	1.74	—	(4.06)
’23	(1.60)	(0.60)	(1.60)	(1.00)	(4.80)
’22	(1.60)	(1.80)	(1.60)	(1.30)	(6.23)
’21	(2.40)	(1.80)	(1.40)	(1.60)	(7.00)
’20	(12.40)	(7.20)	(0.60)	4.44	(13.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	(1)	0	0	—	—
’25	—	—	2	0	1
’19	1	1	1	6	8
’18	1	1	1	1	3
’17	0	0	0	3	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(15)	(8)	(21)	—	—
’25	(11)	(17)	(12)	(12)	(52)
’24	(13)	(19)	(20)	(17)	(69)
’23	(9)	(8)	(13)	(13)	(43)
’22	(11)	(14)	(21)	(10)	(57)
’21	(13)	(12)	(20)	(9)	(54)
’20	(7)	(7)	(6)	(12)	(32)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(15)	(8)	(21)	—	—
’25	(11)	(17)	(12)	(12)	(52)
’24	(13)	(19)	(20)	(17)	(69)
’23	(9)	(8)	(13)	(13)	(43)
’22	(11)	(14)	(21)	(10)	(57)
’21	(13)	(12)	(20)	(9)	(54)
’20	(7)	(7)	(6)	(12)	(32)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	3	4	3	8	—	—	—	—	—	1	(1)		(8.0%)	1	44	171	+394.3%
	Gross margin, %	100.00	100.00	100.00	100.00	0.00	0.00	0.00	0.00	—	4.05	195.62		(95.9) pt	Powerpack Outlook Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to grow 394.3% a year to 2028 — faster than the −8.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(53)	(38)	(34)	(38)	(39)	(53)	(66)	(59)	(75)	(64)	(63)		+2.1%
	EBT margin, %	(1,785.44)	(1,006.10)	(1,092.76)	(465.68)	0.00	0.00	0.00	0.00	0.00	(4,526.12)	5,387.01		(2,740.7) pt
	Net income	(53)	(39)	(30)	(35)	(35)	(53)	(66)	(59)	(75)	(62)	(61)		+1.8%
Per share, $
Per share, $	Revenue	27.69	25.39	12.52	8.96	0.00	0.00	0.00	0.00	0.00	0.04	(0.01)		(51.6%)
	Earnings	(587.20)	(257.94)	(195.20)	(39.60)	(13.40)	(7.00)	(5.87)	(4.80)	(4.06)	(1.79)	(0.86)		(47.5%)
	Cash flow	(422.70)	(103.30)	(133.98)	(35.50)	(8.76)	(7.11)	(5.34)	(3.44)	(3.71)	(1.49)	(0.41)		(46.6%)
	Capex	(10.21)	(1.95)	(11.28)	(0.48)	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(432.91)	(105.24)	(145.26)	(35.98)	(8.76)	(7.11)	(5.34)	(3.44)	(3.71)	(1.49)	(0.41)		(46.8%)
	Book value	(48.08)	(204.71)	(84.39)	(11.84)	0.78	0.60	0.82	(1.15)	(3.94)	(0.92)	(0.08)		(35.5%)
	Shares, m	0	0	0	1	4	8	11	13	19	35	78		+90.0%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00	0.00		0.0
	P/S	24.56	8.76	12.52	3.33	—	—	—	—	—	4.70	0.00		10.8
	P/B	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00	0.00		0.0
	EV/Sales	24.82	11.46	17.41	3.71	—	—	—	—	—	10.09	(66.10)		13.5
	EV/FCF	(1.59)	(2.76)	(1.50)	(0.92)	—	—	—	—	—	(1.51)	(1.36)		(1.7)
Cash, $m
Cash, $m	Operating cash flow	(45)	(16)	(33)	(32)	(32)	(54)	(57)	(43)	(69)	(52)	(56)		+1.5%
	Capex	(1)	0	(3)	0	—	—	—	—	—	—	0		(26.4%)
	Free cash flow	(47)	(16)	(36)	(33)	(32)	(54)	(57)	(43)	(69)	(52)	(56)		+1.2%
Balance, $m
Balance, $m	Working capital	(15)	(25)	(29)	(7)	2	15	8	(16)	(15)	(28)	(6)		+7.6%
	Net debt	1	10	15	3	(12)	(3)	(6)	12	15	22	7		+44.6%
	Shareholders’ equity	(5)	(31)	(21)	(11)	3	5	9	(14)	(73)	(32)	(10)		+22.5%
Returns, %
Returns, %	ROA	(209.02)	(173.50)	(223.25)	(182.86)	(265.13)	(249.92)	(257.32)	(193.93)	(246.60)	(263.36)	(251.66)		(54.3) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	(1,669.72)	(1,744.91)	0.00	0.00	0.00	0.00		0.0 pt
	ROE	210.30	206.19	162.24	172.96	734.77	(1,430.32)	(989.99)	2,069.13	172.24	118.61	256.92		(91.7) pt
People
People	Employees	83	48	56	14	8	9	17	24	23	17	—		(16.2%)
	Revenue/emp, $m	0.04	0.08	0.06	0.58	0.00	0.00	0.00	0.00	0.00	0.08	—		+9.8%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARMP Armata Pharmaceuticals, Inc.	$111.5M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)	Compare
HUMA Humacyte, Inc.	$109.9M	— (loss-making)	— (loss-making)	+34.88% (above 0%: growing)	n/m	+17.85% (above 0%: growing)	(203.20%)	(6,649.26%)	Compare
NERV Minerva Neurosciences, Inc	$109.8M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
OTLK Outlook Therapeutics, Inc.	$106.9M	— (loss-making)	— (loss-making)	−99.42% (below 0%: shrinking)	n/m	−76.54% (below 0%: shrinking)	(95.40%)	(124,255.17%)
VYGR Voyager Therapeutics, Inc.	$106.0M	— (loss-making)	— (loss-making)	−69.97% (below 0%: shrinking)	n/m	+37.08% (above 0%: growing)	100.00%	(658.25%)	Compare
ANIX ANIXA BIOSCIENCES INC	$105.3M	— (loss-making)	— (loss-making)	0.00%	n/m	−17.14% (below 0%: shrinking)	0.00%	0.00%	Compare
NBP NovaBridge Biosciences	$105.3M	— (loss-making)	— (loss-making)	−88.54% (below 0%: shrinking)	n/m	+34.25% (above 0%: growing)	100.00%	0.00%	Compare
AVXL Anavex Life Sciences Corp.	$102.9M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
HURA TuHURA Biosciences, Inc.	$102.6M	— (loss-making)	—	—	n/m	−70.46% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$105.7M	—	—	0.00%	—	+0.35%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 1 June 2026

Ownership

Directors and executive officers, together 1.80%

GMS Ventures and Investments 21.30%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Outlook Therapeutics, Inc. (OTLK) Latest News

9 Oct

Impact 4 · 8:30 AM · GlobeNewswire

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

6 Oct

Impact 4 · 9:20 AM · GlobeNewswire

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

1 Oct

Impact 4 · 9:01 AM · GlobeNewswire

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

10 Sep

Impact 4 · 9:10 AM

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

27 Aug

Impact 3 · 4:05 PM

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

17 Aug

Impact 4 · 10:00 AM transcript

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

15 Aug

Impact 3 · 2:12 AM

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

14 Aug

Impact 5 · 7:15 AM

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Impact 3 · 11:04 AM · MarketBeat transcript

Oncobiologics Q3 Earnings Call Highlights

Impact 3 · 8:30 AM · Moby transcript

Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary

Impact 3 · 8:25 AM

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

13 Aug

Impact 4 · 6:31 AM · Stocktwits

Why Did OTLK Stock Crash In Pre-Market Today?

12 Aug

Impact 4 · 4:01 PM

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Impact 3 · 9:45 PM

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

10 Aug

Impact 4 · 11:27 AM

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

29 Jul

Impact 4 · 9:10 PM

Outlook Therapeutics (OTLK) Is Down 24.3% After Landmark FDA Wet AMD Drug Approval - Has The Bull Case Changed?

Impact 4 · 5:08 PM

Outlook Therapeutics (OTLK) Wins FDA Approval, Is The Valuation Already Priced In?

28 Jul

Impact 4 · 5:31 PM

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

27 Jul

Impact 5 · 7:13 AM · pharmaceutical-technology.com

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Impact 5 · 2:47 AM · Stocktwits

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Impact 4 · 1:45 PM · Stocktwits

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

Impact 4 · 7:12 AM · InvestorsHub

Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD

24 Jul

Impact 5 · 7:47 PM · Stocktwits

OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab

Impact 5 · 2:40 PM

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

23 Jul

Impact 5 · 1:00 PM · Stocktwits

OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’

14 Jul

Impact 4 · 2:08 PM

Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA

17 Jun

Impact 4 · 10:20 AM

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

16 Jun

Impact 4 · 4:08 PM

Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In

Impact 4 · 1:47 PM · Stocktwits

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

Impact 4 · 8:02 AM

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Outlook Therapeutics, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to September

Outlook Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 1 June 2026

Ownership

Outlook Therapeutics, Inc. (OTLK) Latest News

9 Oct

6 Oct

1 Oct

10 Sep

27 Aug

17 Aug

15 Aug

14 Aug

13 Aug

12 Aug

10 Aug

29 Jul

28 Jul

27 Jul

24 Jul

23 Jul

14 Jul

17 Jun

16 Jun

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to September

Outlook Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 1 June 2026

Ownership

Outlook Therapeutics, Inc. (OTLK) Latest News

9 Oct

6 Oct

1 Oct

10 Sep

27 Aug

17 Aug

15 Aug

14 Aug

13 Aug

12 Aug

10 Aug

29 Jul

28 Jul

27 Jul

24 Jul

23 Jul

14 Jul

17 Jun

16 Jun

Stockrow Weekly